Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of IBI354 with or without pertuzumab versus THP as first-line treatment for unresectable locally advanced or metastatic HER2-positive breast cancer
CTR20260256Phase 3Active
- Sponsor
- Innovent Biologics
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of IBI354 in breast cancer, sponsored by Innovent Biologics. Started Feb 2026; status: active.
02
Drugs
IBI354
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20260256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260256.